Search company, investor...
Search
Roivant Sciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

roivant.com

Founded Year

2014

Stage

Reverse Merger | IPO

Total Raised

$2.5B

Market Cap

2.34B

Stock Price

3.24

About Roivant Sciences

Roivant Sciences (NASDAQ: ROIV) focuses on developing and commercializing therapies through wholly- or majority-owned subsidiary companies including, Axovant, Myovant, Dermavant, Enzyvant, and Urovant.

Roivant Sciences Headquarters Location

151 W 42nd Street 15th Floor

New York, New York, 10036,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Roivant Sciences

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Roivant Sciences in 3 CB Insights research briefs, most recently on Jul 6, 2022.

Roivant Sciences Patents

Roivant Sciences has filed 6 patents.

The 3 most popular patent topics include:

  • Amines
  • Hepatology
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/14/2019

12/21/2021

Hepatology, Stimulants, Amines, Transcription factors, Piperidines

Grant

Application Date

11/14/2019

Grant Date

12/21/2021

Title

Related Topics

Hepatology, Stimulants, Amines, Transcription factors, Piperidines

Status

Grant

Latest Roivant Sciences News

Roivant Sciences : Investor Day 2022 Presentation

Sep 28, 2022

09/28/2022 | 11:06am EDT Message : Forward-Looking Statements This presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Our forward- looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of VTAMA and our other existing and future product candidates, the timing and expectations of potential regulatory submissions, the availability and success of topline results from our ongoing clinical trials, any commercial potential of VTAMA and our other product candidates, including but not limited to the anticipated timeline of commercial coverage of VTAMA, any pending or potential litigation, including but not limited to our expectations regarding the outcome of any such litigation and costs and expenses associated with such litigation, and our business strategies, financial condition, and trends, competitive position, potential growth opportunities, and expectations or probabilities for success. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the sections captioned "Risk Factors" and "Forward-Looking Statements" of our filings with the U.S. Securities and Exchange Commission, available at www.sec.gov and investor.roivant.com. We operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Today's discussion will include statements by a panel of physicians regarding VTAMA. The views and opinions expressed by our panelists today are their own. The moderator of the panel, and our panelists, may make forward-looking statements and the safe harbor rules described above govern such statements. Disclaimer Today's discussions and presentation are intended for the investor community only; they are not intended to promote the product candidates referenced herein or otherwise influence healthcare prescribing decisions. For investor audiences only

Roivant Sciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Roivant Sciences Rank

  • When was Roivant Sciences founded?

    Roivant Sciences was founded in 2014.

  • Where is Roivant Sciences's headquarters?

    Roivant Sciences's headquarters is located at 151 W 42nd Street, New York.

  • What is Roivant Sciences's latest funding round?

    Roivant Sciences's latest funding round is Reverse Merger.

  • How much did Roivant Sciences raise?

    Roivant Sciences raised a total of $2.5B.

  • Who are the investors of Roivant Sciences?

    Investors of Roivant Sciences include Montes Archimedes Acquisition, SK Holdings, Sumitomo Dainippon Pharma, SoftBank Group, RTW Investments and 5 more.

  • Who are Roivant Sciences's competitors?

    Competitors of Roivant Sciences include Redesign Science and 4 more.

You May Also Like

insitro Logo
insitro

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.

OPTT Logo
OPTT

OPTT is a digital mental health platform that allows providers to offer clinically validated digital therapy. It specializes in cognitive behavioral therapy.

Naluri Logo
Naluri

Naluri provides personalized coaching and uses evidence-based Cognitive Behavioural Therapy and Motivational Interviewing techniques to strengthen users' mental resilience and resolve to achieve and sustain better health outcomes such as weight loss, better stress management, or reduction in blood pressure or blood sugar levels. Naluri was founded in 2017 and is based in Kuala Lumpur, Malaysia.

Sympatient Logo
Sympatient

Sympatient provides anxiety therapy in patients' homes with mobile virtual reality, apps, and real therapists. It provides therapeutic such as exposure therapy and CBT for anxiety disorders. The company was founded in 2017 and is based in Hamburg, Germany.

Koa Health Logo
Koa Health

Koa Health is a digital mental healthcare provider offering a range of personalized mental health solutions backed by science and designed to improve user wellbeing.

HelloBetter Logo
HelloBetter

HelloBetter develops and offers psychological digital therapeutics translating scientifically-validated, cognitive behavioral therapy approaches into an online course experience. HelloBetter's prevention and treatment courses cover major mental health issues (e.g. depression, anxiety, insomnia, vaginismus, and chronic pain). The company was founded in 2015 and is based in Hamburg, Germany.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.